<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576690</url>
  </required_header>
  <id_info>
    <org_study_id>R3470-3471-3479-EBOV-1846</org_study_id>
    <nct_id>NCT03576690</nct_id>
  </id_info>
  <brief_title>R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus</brief_title>
  <official_title>Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Ebola Virus Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN3470-3471-3479</intervention_name>
    <other_name>REGN-EB3</other_name>
    <other_name>InmazebÂ®</other_name>
    <other_name>atoltivimab, maftivimab, and odesivimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or females in an Ebola endemic region with documented positive polymerase chain&#xD;
             reaction (PCR) for Ebola virus infection who are symptomatic&#xD;
&#xD;
          -  Ability to provide informed consent personally or by a legal representative if the&#xD;
             patient is unable to do so, based on local laws and regulations&#xD;
&#xD;
          -  REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as&#xD;
             defined in the protocol&#xD;
&#xD;
          -  Children of any age will be eligible for enrollment, as defined in the protocol&#xD;
&#xD;
          -  Neonates born to an infected mother who has not yet cleared the Ebola virus are&#xD;
             eligible for enrollment, as defined in the protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Negative EBOV diagnostic test result&#xD;
&#xD;
          -  A patient who, in the judgment of the investigator, will be unlikely to comply with&#xD;
             the requirements of this protocol&#xD;
&#xD;
          -  Any serious medical condition that, in the opinion of the site investigator, would&#xD;
             place the patient at an unreasonable increased risk through participation in this&#xD;
             study, including any past or concurrent conditions&#xD;
&#xD;
          -  Eligible for an ongoing randomized clinical trial with REGN-EB3&#xD;
&#xD;
        NOTE: Other protocol defined inclusion / exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positive Ebola Virus (EBOV) diagnostic test</keyword>
  <keyword>symptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

